Related content

Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients

By de Mendoza Carmen   Morelló Judit   Garcia-Gascó Pilar   Rodríguez-Novoa Sonia   Soriano Vincent  

Expert Opinion on Pharmacotherapy, Vol. 8, Iss. 6, 2007-04 ,pp. : 839-850

Informa Healthcare

Access to resources Recommend Favorite

Hepatotoxicity Following Nevirapine-Containing Regimens in Hiv-1-Infected Individuals

By de Maat M.M.R.   Mathot R.A.A.   Veldkamp A.I.   Huitema A.D.R.   Mulder J.W.   Meenhorst P.L.   van Gorp E.C.M.   Carlier H.   Beijnen J.H.  

Pharmacological Research, Vol. 46, Iss. 3, 2002-09 ,pp. : 295-300

Academic Press

Access to resources Recommend Favorite

Meta-analysis of once-daily and twice-daily lopinavir/ritonavir combined with NRTIs in HIV-1-infected, antiretroviral-naive patients

By van Wyk Jean   Qaqish Roula   Hollar Kimberly   White Kelly   D’’Amico Ronald   Norton Michael   Chiu Yi-Lin   King Martin  

Future Virology, Vol. 7, Iss. 1, 2012-01 ,pp. : 103-113

Future Medicine

Access to resources Recommend Favorite

Nevirapine-based HAART is more effective than protease inhibitor (PI)-based HAART in antiretroviral therapy-naive pregnant women with HIV infection

By  

Inpharma, Vol. 1, Iss. 1590, 2007-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Raltegravir to the rescue for treatment-naive patients with HIV-1

By  

Inpharma, Vol. 1, Iss. 1652, 2008-01 ,pp. : 11-12

Adis International

Access to resources Recommend Favorite